Trial Profile
A Phase 2 Investigator Initiated Study to Determine the Efficacy and Safety of TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Denifanstat (Primary)
- Indications Astrocytoma; Glioblastoma
- Focus Therapeutic Use
- 24 Apr 2023 Primary endpoint (Progression free survival) has been met according to Results published in the Clinical Cancer Research.
- 24 Apr 2023 Results assessing safety and efficacy of denifanstat with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma published in the Clinical Cancer Research
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress